EGFR and breast cancer: Similarly, loss of HER2, alternative signaling through other RTKs such as insulin-like grow factor 1 receptor (IGF-1R) and epidermal growth factor receptor (EGFR) and mutations in downstream signaling elements that lead to the subsequent activation of cell survival mechanisms may orchestrate the development of anti-HER2 drugs resistance in HER2-enriched BC [51].